tirzepatide subcutaneous injection Weightloss 12-Week Program Tirzepatide | GLP1 | Medical

Quick Answer: Tirzepatide can cause nausea and vomiting in 1231% of patients, with symptoms typically occurring during initial treatment or dose increases and generally diminishing over time

Its important to monitor your progress to see how your body responds and identify the appropriate strength thats effective and tolerable for you

Neither tirzepatide nor retatrutide should be combined with other GLP-1 agonists like semaglutide

It is essential to monitor for serious allergic reactions, manifesting as recurrent fever, upper arm swelling, and bowel obstruction

This effect could be particularly problematic in patients with pre-existing conditions affecting gastric motility